Nido Biosciences Overview
- Year Founded
-
2018
- Status
-
Out of Business
- Employees
-
11
- Latest Deal Type
-
Out of Business
Nido Biosciences General Information
Description
Developer of a healthcare platform intended to develop precision medicines and small-molecule therapeutics to treat neurodegenerative diseases. The company uses a functional genomics discovery platform based on human cell lines that leverages tailored screens to identify novel therapeutic targets for multiple neuromuscular and neurodegenerative diseases and human genetics, enabling healthcare professionals to treat the underlying biology of disease and restore healthy cell function to create precise medications.
Contact Information
Website
www.nidobio.comCorporate Office
- 59 West Dedham Street
- Unit 180430
- Boston, MA 02118
- United States
Corporate Office
- 59 West Dedham Street
- Unit 180430
- Boston, MA 02118
- United States
Nido Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Out of Business | 30-Dec-2025 | Completed | Out of Business | |||
| 6. Later Stage VC | Completed | Clinical Trials - Phase 1 | ||||
| 5. Later Stage VC (Series B) | 15-May-2023 | Completed | Clinical Trials - Phase 1 | |||
| 4. Early Stage VC (Series A1) | 29-Nov-2022 | Completed | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC (Series A) | 08-Sep-2020 | Completed | Clinical Trials - Phase 1 | |||
| 2. Seed Round | 10-Sep-2019 | $4M | $4M | Completed | Clinical Trials - Phase 1 | |
| 1. University Spin-Out | 01-Jan-2018 | Completed | Startup |
Nido Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-1 | ||||||||
| Series B | ||||||||
| Series A-1 | 37,000,000 | $0.000100 | $0.1 | $1.25 | $1.25 | 1x | $1.25 | 33.71% |
| Seed | 4,000,000 | $0.000100 | $0.08 | $1 | $1 | 1x | $1 | 3.64% |
Nido Biosciences Patents
Nido Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250263396-A1 | Crystalline forms of 3-(5-(2-hydroxy-2- methylpropoxy)-6-methypyrazin-2-yl)-1h-indole-7-carbonitrile | Pending | 26-Jan-2024 | ||
| WO-2025160320-A1 | Crystalline forms of 3-(5-(2-hydroxy-2-methylpropoxy)-6-methylpyrazin-2-yl)-1h-indole-7-carbonitrile | Pending | 26-Jan-2024 | ||
| AU-2023206373-A1 | Crystalline forms of 3-(5-(2-hydroxy-2-methylpropoxy)-6-methylpyrazin-2-yl)-1h-indole-7-carbonitrile | Pending | 14-Jan-2022 | ||
| EP-4463449-A1 | Crystalline forms of 3-(5-(2-hydroxy-2-methylpropoxy)-6-methylpyrazin-2-yl)-1h-indole-7-carbonitrile | Inactive | 14-Jan-2022 | ||
| US-12168650-B2 | Crystalline forms of 3-(5-(2-hydroxy-2-methylpropoxy)-6-methylpyrazin-2-yl)-1h-indole-7-carbonitrile | Active | 14-Jan-2022 | C07D401/04 |
Nido Biosciences Signals
Nido Biosciences FAQs
-
When was Nido Biosciences founded?
Nido Biosciences was founded in 2018.
-
Where is Nido Biosciences headquartered?
Nido Biosciences is headquartered in Boston, MA.
-
What is the size of Nido Biosciences?
Nido Biosciences has 11 total employees.
-
What industry is Nido Biosciences in?
Nido Biosciences’s primary industry is Drug Discovery.
-
Is Nido Biosciences a private or public company?
Nido Biosciences is a Private company.
-
What is Nido Biosciences’s current revenue?
The current revenue for Nido Biosciences is .
-
How much funding has Nido Biosciences raised over time?
Nido Biosciences has raised $109M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process